Eyenovia (EYEN)
(Delayed Data from NSDQ)
$0.45 USD
0.00 (1.00%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $0.45 0.00 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.45 USD
0.00 (1.00%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $0.45 0.00 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Zacks News
Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Eyenovia (EYEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Eyenovia (EYEN) delivered earnings and revenue surprises of -5.88% and 98.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
by Zacks Equity Research
Eyenovia (EYEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
by Zacks Equity Research
Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of -5.88% and 99.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of 11.54% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.
Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.
Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Regeneron (REGN), among others.
Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.
Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.
Bausch Acquires License for Myopia Solution from Eyenovia
by Zacks Equity Research
Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.
Will Eyenovia Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Eyenovia
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.
Eyenovia, Inc. (EYEN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).
All You Need to Know About Eyenovia, Inc. (EYEN) Rating Upgrade to Strong Buy
by Zacks Equity Research
Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Can European Buyouts Aid Canopy Growth's (CGC) Q2 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.
What's in Store for Applied Materials' (AMAT) Q4 Earnings?
by Zacks Equity Research
Applied Materials' (AMAT) technology leadership position and strong product line in Display and Services are likely to reflect on fiscal fourth-quarter results.
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q2 Earnings?
by Zacks Equity Research
A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.
Overstock (OSTK) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Overstock's (OSTK) third-quarter results are likely to reflect strength across retail and blockchain businesses.
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress, when it reports Q3 results.